Zenas BioPharma, Inc. ZBIO
28.65 USD +0.27 (+0.95%)
Nov 4, 2026, 12:51 PM EST
28.01 Day range 29.80
13.50 52-week range 44.60
- YTD
- -21.10%
- 1 year
- -4.34%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 47.88 +67.1% upside
Now 28.65
- Target (low)
- 32.00
- Target (mean)
- 47.88
- Target (high)
- 59.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy0
- Buy7
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 8
- 2 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.27 | -1.31 – -1.23 | -1.22 | -4.1% | 0 | 0.0% | 2 |
| Next quarter | -1.28 | -1.31 – -1.25 | -1.39 | +7.9% | 14.07M | 0.0% | 2 |
| Current year | -5.62 | -5.83 – -5.40 | -4.83 | -16.2% | 12.26M | +22.6% | 2 |
| Next year | -4.66 | -5.11 – -4.21 | -5.62 | +17.0% | 57.93M | +372.5% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 13, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 30, 2026 | Citigroup | Maintained | Buy | Buy |
| Sep 30, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Sep 30, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 14, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Aug 14, 2026 | Guggenheim | Reiterated | Buy | Buy |
| Aug 14, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| May 15, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 14, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Mar 17, 2026 | Citigroup | Maintained | Buy | Buy |
| Mar 17, 2026 | Guggenheim | Maintained | Buy | Buy |
| Mar 17, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Mar 17, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 10, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 6, 2026 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| Dec 22, 2025 | Wedbush | Reiterated | Outperform | Outperform |
| Nov 26, 2025 | Evercore ISI Group | Initiated | — | Outperform |
| Nov 13, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| Oct 28, 2025 | Citigroup | Maintained | Buy | Buy |
| Oct 28, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| Oct 28, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 9, 2025 | Wedbush | Maintained | Outperform | Outperform |
| Oct 9, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 16, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 20, 2025 | Wedbush | Initiated | — | Outperform |
| Mar 12, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Mar 12, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 4, 2025 | Wolfe Research | Initiated | — | Outperform |
| Dec 16, 2024 | HC Wainwright & Co. | Initiated | — | Buy |
| Dec 11, 2024 | Morgan Stanley | Maintained | Overweight | Overweight |
